Research programme: microRNA therapeutics - Microlin Bio

Drug Profile

Research programme: microRNA therapeutics - Microlin Bio

Alternative Names: Colomiralin™; Lumiralin™; miR 17 5p inhibitor - Microlin Bio; miR 17 inhibitors - Microlin Bio; miR 21 inhibitor - Microlin Bio; miR 484 inhibitor - Microlin Bio; Omiralin™; Promiralin™

Latest Information Update: 14 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ohio State University
  • Developer Microlin Bio; Ohio State University
  • Class Antisense oligonucleotides; MicroRNAs; Oligonucleotides
  • Mechanism of Action MicroRNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Lung cancer

Most Recent Events

  • 12 Jan 2016 Preclinical data released by Microlin Bio
  • 24 Sep 2015 Research programme: microRNA therapeutics - Microlin Bio is available for licensing as of 24 Sep 2015. http://www.microlinbio.com/
  • 24 Sep 2015 Preclinical trials in Lung cancer in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top